Literature DB >> 31483694

Minimum Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective, Lesion Based Analyses of Patients Treated with Radical Prostatectomy.

Sami-Ramzi Leyh-Bannurah1,2, Mykyta Kachanov1, Dirk Beyersdorff1,3, Zhe Tian4, Pierre I Karakiewicz4, Derya Tilki1,2, Margit Fisch2, Tobias Maurer1,2, Markus Graefen1, Lars Budäus1.   

Abstract

PURPOSE: We analyzed the number of multiparametric magnetic resonance imaging targeted biopsy cores per lesion needed to detect prostate cancer in patients treated with radical prostatectomy.
MATERIALS AND METHODS: Analyses focused on targeted biopsy of magnetic resonance imaging lesions suspicious for prostate cancer with a PI-RADS® (Prostate Imaging Reporting and Data System) score of 3 or greater and consecutive radical prostatectomy. Descriptive statistics included the frequency/proportion and IQR. Multivariable logistic regression analyses on the per lesion level were used to predict the number of targeted biopsies with prostate cancer.
RESULTS: In the total cohort of 771 radical prostatectomy cases 437 (57%) and 334 (43%) were systematic transrectal ultrasound guided biopsy naïve or had 1 or more prior negative systematic transrectal ultrasound guided biopsies, respectively. A maximum PI-RADS score of 3, 4 and 5 was present in 67 (8.7%), 567 (74%) and 137 patients (18%), respectively. A total of 1,459 multiparametric magnetic resonance imaging lesions suspicious for prostate cancer were identified for analysis. Prostate cancer was detected based on an initial, second, third, or fourth or greater targeted biopsy in 79%, 92%, 98% and 100% of cases, respectively. The rate of prostate cancer detection on the first targeted biopsy core increased with higher PI-RADS scores of 3, 4 and 5 (67%, 79% and 87%, respectively). The number of prior negative systematic transrectal ultrasound guided biopsies and pathological tumor stage emerged as independent predictors on multivariate analysis, addressing the need for 2 or more targeted biopsy cores to detect clinically significant prostate cancer.
CONCLUSIONS: Radical prostatectomy based analyses demonstrated that most cancers could be detected by 2 targeted biopsies only while in a minority of cases 3 or more targeted biopsies were necessary. Such findings might indicate that the targeted biopsy procedure and the related technology have improved, especially in patients with intermediate/high risk prostate cancer.

Entities:  

Keywords:  biopsy; diagnostic imaging; magnetic resonance imaging; prostatic neoplasms; risk

Mesh:

Year:  2019        PMID: 31483694     DOI: 10.1097/JU.0000000000000527

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  What is the ideal number of biopsy cores per lesion in targeted prostate biopsy?

Authors:  Gokhan Sonmez; Turev Demirtas; Sevket T Tombul; Figen Ozturk; Abdullah Demirtas
Journal:  Prostate Int       Date:  2020-04-23

2.  Prostate cancer: diagnostic yield of modified transrectal ultrasound-guided twelve-core combined biopsy (targeted plus systematic biopsies) using prebiopsy magnetic resonance imaging.

Authors:  Chorog Song; Sung Yoon Park
Journal:  Abdom Radiol (NY)       Date:  2021-06-28

3.  Diagnostic accuracy and clinical implications of robotic assisted MRI-US fusion guided target saturation biopsy of the prostate.

Authors:  Christian Wetterauer; Pawel Trotsenko; Marc Olivier Matthias; Christian Breit; Nicola Keller; Anja Meyer; Philipp Brantner; Tatjana Vlajnic; Lukas Bubendorf; David Jean Winkel; Maciej Kwiatkowski; Hans Helge Seifert
Journal:  Sci Rep       Date:  2021-10-12       Impact factor: 4.379

4.  Assessing the accuracy of multiparametric MRI to predict clinically significant prostate cancer in biopsy naïve men across racial/ethnic groups.

Authors:  Julio Meza; Rilwan Babajide; Ragheed Saoud; Jeanne M Horowitz; David D Casalino; Adam B Murphy; Jamila Sweis; Josephine Abelleira; Irene Helenowski; Borko Jovanovic; Scott Eggener; Frank H Miller
Journal:  BMC Urol       Date:  2022-07-18       Impact factor: 2.090

5.  Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma.

Authors:  Zhaoxin Guo; Xiaolin Hu; Renguang Lv; Yongzhen Zhang; Liwei Meng; Zhaoxu Liu; Lei Yan
Journal:  Dis Markers       Date:  2022-08-17       Impact factor: 3.464

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.